PATENT CLAIM ANALYSIS

Application Number: 15900405
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["514", "303000"]

Abstract:
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Claim (Index 32):
The method of  claim 28 , wherein said measuring comprises adding scintillation fluid to the aspirated GF/C glass filter.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 88.0
- Lexical Diversity: 1.44737
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14011174', '11491540', '10460752', '10732897', '11694935']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8337180031670615
- 35 USC 102 Novelty (BERT): 0.5417561759946241
- Combined Prediction Score: 0.8045218204498178
- Mean Citation Score: 355.22914799999984
- Max Citation Score: 430.1475
- Similarity Product: 212.4352365915477

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test